On the basis of the previous arguments, the present narrative review will be focused on two main topics: (i) pathophysiologic functions of IL-4 and IL-13 in type 2 asthma; and (ii) the role of dupilumab as an add-on biological therapy of severe asthma. This evidence concerns the gene IL4 and asthma.